

NCCN Biomarkers Compendium®

Printed by Larry Page on 7/10/2015 4:42:21 PM. For personal use only. Not approved for distribution. The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version, please visit NCCN.org/biomarkers.

Disease Description:	Acute Lymphoblastic Leukemia
Specific Indication:	T-ALL
Molecular Abnormality:	Comprehensive flow cytometric immunophenotyping to include B, T and myeloid lineage markers
Test:	Comprehensive flow cytometric immunophenotyping to include B, T and myeloid lineage markers
Chromosome:	
Gene Symbol:	
Test Detects:	Protein expression
Methodology:	Flow cytometry
NCCN Category of Evidence:	2A
Specimen Types:	
NCCN Recommendation - Clinical Decision:	The initial immunophenotyping panel should be sufficiently comprehensive to establish a leukemia associated phenotype (LAP) that may include expression of non-lineage antigens. These LAP are useful in classification, particularly mixed lineage leukemias, and as a signature for minimal residual disease (MRD) detection.
Test Purpose:	Classification, Diagnostic
When to Test:	
Guideline Page with Test Recommendation:	ALL-1 Page:5, ALL-A Page:12
Notes:	Typical Immunophenotype, T-ALL: TdT+. variable for all of the following: CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD34. •Pro-T-ALL: cCD3+, CD7+, CD1a-, CD2-, CD4-, CD8-, CD34+/ Pre-T-ALL: cCD3+, CD7+, CD1a-, CD2+, CD4-, CD8-, CD34+/ •Cortical T-ALL: cCD3+, CD7+, CD1a+, CD2+, CD4+, CD8+, CD34 •Medullary T-ALL: cCD3+, sCD3+, CD7+, CD1a-, CD2+, CD4+ or CD8+, CD34 •ETP T-ALL: Lack of CD1a and CD8 expression, weak CD5 expression with less than 75% positive blasts, and expression of one or more of the following myeloid or stem cell markers on at least 25% of lymphoblasts: CD117, CD34, HLA-DR, CD13, CD33, CD11b, and/or CD65.
	Guideline: Acute Lymphoblastic Leukemia v.1.2014, as of 12/4/2014 10:22:20 AM NCCN Reference ID: 1 Under Review

The NCCN Biomarkers Compendium® is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. © 2015. The NCCN Biomarkers Compendium® and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. The NCCN Biomarkers Compendium® neither represents an all-inclusive listing of biomarker tests used in cancer treatment nor every oncology-related use and indication for biomarker testing. Any clinician seeking to apply or consult the NCCN Biomarkers Compendium® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.